Clinical trial

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT03765918

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Pembrolizumab 200 mg Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Radiotherapy 60 Gray Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Radiotherapy 66 Gray Find medicine records · Find other trials using this name

RADIATION · Unmapped registry intervention Radiotherapy 70 Gray Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Cisplatin 100 mg/m^2 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Design: INTERVENTIONAL · Status: ACTIVE NOT RECRUITING · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-12-17

PhasePHASE3

Conditions

Head and Neck Neoplasmsunresolved

Interventions

Pembrolizumab 200 mgBIOLOGICAL

Radiotherapy 60 GrayRADIATION

Radiotherapy 66 GrayRADIATION

Radiotherapy 70 GrayRADIATION

Cisplatin 100 mg/m^2DRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Mapped research locations

New YorkNew York, United States4 RosarioSanta Fe Province, Argentina4 PortlandOregon, United States3 Buenos AiresArgentina3 TokyoJapan3 TorontoOntario, Canada2 ParisFrance2 Washington D.C.District of Columbia, United States2 OrlandoFlorida, United States2 DetroitMichigan, United States2 BudapestHungary2 São PauloBrazil2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03765918 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.